Pfizer Inc. (NYSE:PFE) received drug approval for pneumococcal conjugate vaccine


Dallas, Texas 07/11/2013 (Financialstrend) – On Wednesday, the drug company Pfizer, Inc. (NYSE:PFE) received approval for its pneumococcal conjugate vaccine in Europe. This vaccine can be used by older-aged groups. Prevenar 13 is the name of the vaccine released by Pfizer, Inc. (NYSE:PFE); this approval has to do with the usage of this vaccine expanded to adults aged between 18 and 49 years old. In the European Union, the drug was previously approved for six weeks to people aged from 17 to 50 years old.

The “Pfizer Inc. – Product Pipeline Review – 2013” is recently released by Global Market Direct, which provides data on research and development of Pfizer, Inc. (NYSE:PFE ). It also involves information of dormant projects, features on discontinued projects, complete with latest updates and current developmental pipelines. In Boston, Pfizer, Inc. (NYSE:PFE) announced recently the results of the AMPLIFY (6 month trial) 3rd Phase. The trial involved 5,395 patients with acute PE (pulmonary embolism) and/or VTE (venous thromboembolism) which includes symptomatic DVT (deep vein thrombosis). In this examination, the company achieved the initial efficacy of non inferiority to reduce the composite endpoint of VTE-related death or VTE, to the care current standard.

After reaching the intraday high price of $28.51, the share price of Pfizer, Inc. (NYSE:PFE) closed at $28.44 with an intraday low price of $28.31. The share price rose by 0.32%, closing on Wednesday at $28.47.

The 52-week high and low was $31.15 and $22.00 respectively. With 7.09 billion total outstanding shares, the market capitalization amounts to $201.73 billion. The intraday share trading volume for yesterday was 100.00 million, whereas the average trading volume of Pfizer, Inc. (NYSE:PFE) heads up to 89.34 million. Institutional owners hold 74% of the total outstanding shares.